nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—MTNR1B—polycystic ovary syndrome	0.844	1	CbGaD
Agomelatine—Midodrine—ADRA1D—polycystic ovary syndrome	0.00177	0.234	CrCbGaD
Agomelatine—Midodrine—ADRA1B—polycystic ovary syndrome	0.00151	0.2	CrCbGaD
Agomelatine—Midodrine—ADRA1A—polycystic ovary syndrome	0.00102	0.134	CrCbGaD
Agomelatine—Melatonin—MTNR1B—polycystic ovary syndrome	0.00101	0.133	CrCbGaD
Agomelatine—Naproxen—AKR1C3—polycystic ovary syndrome	0.000833	0.11	CrCbGaD
Agomelatine—Indomethacin—AKR1C3—polycystic ovary syndrome	0.000675	0.0892	CrCbGaD
Agomelatine—Migraine—Metformin—polycystic ovary syndrome	0.000595	0.0592	CcSEcCtD
Agomelatine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000541	0.0538	CcSEcCtD
Agomelatine—Influenza—Metformin—polycystic ovary syndrome	0.000523	0.052	CcSEcCtD
Agomelatine—Infestation NOS—Metformin—polycystic ovary syndrome	0.000466	0.0463	CcSEcCtD
Agomelatine—Infestation—Metformin—polycystic ovary syndrome	0.000466	0.0463	CcSEcCtD
Agomelatine—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000441	0.0438	CcSEcCtD
Agomelatine—Hepatitis—Metformin—polycystic ovary syndrome	0.000418	0.0416	CcSEcCtD
Agomelatine—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000411	0.0409	CcSEcCtD
Agomelatine—Eye disorder—Metformin—polycystic ovary syndrome	0.000391	0.0389	CcSEcCtD
Agomelatine—Vision blurred—Metformin—polycystic ovary syndrome	0.000343	0.0341	CcSEcCtD
Agomelatine—Tremor—Metformin—polycystic ovary syndrome	0.000341	0.0339	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000308	0.0306	CcSEcCtD
Agomelatine—Infection—Metformin—polycystic ovary syndrome	0.000295	0.0294	CcSEcCtD
Agomelatine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000291	0.029	CcSEcCtD
Agomelatine—Skin disorder—Metformin—polycystic ovary syndrome	0.000289	0.0287	CcSEcCtD
Agomelatine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000287	0.0286	CcSEcCtD
Agomelatine—Indomethacin—PPARG—polycystic ovary syndrome	0.00028	0.0371	CrCbGaD
Agomelatine—Melatonin—CYP19A1—polycystic ovary syndrome	0.000273	0.0361	CrCbGaD
Agomelatine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000267	0.0265	CcSEcCtD
Agomelatine—Somnolence—Metformin—polycystic ovary syndrome	0.000264	0.0263	CcSEcCtD
Agomelatine—Dyspepsia—Metformin—polycystic ovary syndrome	0.000262	0.026	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000257	0.0255	CcSEcCtD
Agomelatine—Fatigue—Metformin—polycystic ovary syndrome	0.000256	0.0255	CcSEcCtD
Agomelatine—Constipation—Metformin—polycystic ovary syndrome	0.000254	0.0253	CcSEcCtD
Agomelatine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000243	0.0242	CcSEcCtD
Agomelatine—Urticaria—Metformin—polycystic ovary syndrome	0.000236	0.0235	CcSEcCtD
Agomelatine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000235	0.0234	CcSEcCtD
Agomelatine—Asthenia—Metformin—polycystic ovary syndrome	0.000213	0.0212	CcSEcCtD
Agomelatine—Pruritus—Metformin—polycystic ovary syndrome	0.00021	0.0209	CcSEcCtD
Agomelatine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000203	0.0202	CcSEcCtD
Agomelatine—Melatonin—CYP1A1—polycystic ovary syndrome	0.000201	0.0266	CrCbGaD
Agomelatine—Dizziness—Metformin—polycystic ovary syndrome	0.000197	0.0195	CcSEcCtD
Agomelatine—Vomiting—Metformin—polycystic ovary syndrome	0.000189	0.0188	CcSEcCtD
Agomelatine—Headache—Metformin—polycystic ovary syndrome	0.000186	0.0185	CcSEcCtD
Agomelatine—Nausea—Metformin—polycystic ovary syndrome	0.000177	0.0176	CcSEcCtD
Agomelatine—MTNR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	4.01e-05	0.00029	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—ADRB2—polycystic ovary syndrome	3.97e-05	0.000287	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	3.92e-05	0.000284	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ADRA1D—polycystic ovary syndrome	3.89e-05	0.000282	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	3.89e-05	0.000282	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—SCT—polycystic ovary syndrome	3.85e-05	0.000279	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—CYP19A1—polycystic ovary syndrome	3.81e-05	0.000276	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.79e-05	0.000274	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—ADRB3—polycystic ovary syndrome	3.77e-05	0.000273	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	3.76e-05	0.000272	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	3.75e-05	0.000271	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—LHB—polycystic ovary syndrome	3.73e-05	0.00027	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—INHBB—polycystic ovary syndrome	3.69e-05	0.000267	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—GNAS—polycystic ovary syndrome	3.68e-05	0.000267	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	3.68e-05	0.000266	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	3.67e-05	0.000266	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—GNRH1—polycystic ovary syndrome	3.64e-05	0.000264	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—CYP1A1—polycystic ovary syndrome	3.6e-05	0.00026	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	3.55e-05	0.000257	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—SCT—polycystic ovary syndrome	3.49e-05	0.000253	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	3.49e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTGER3—polycystic ovary syndrome	3.46e-05	0.00025	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LHCGR—polycystic ovary syndrome	3.46e-05	0.00025	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.44e-05	0.000249	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.43e-05	0.000248	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IRS2—polycystic ovary syndrome	3.43e-05	0.000248	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.36e-05	0.000243	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—LEP—polycystic ovary syndrome	3.36e-05	0.000243	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—LEP—polycystic ovary syndrome	3.36e-05	0.000243	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	3.33e-05	0.000241	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	3.33e-05	0.000241	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	3.31e-05	0.00024	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	3.25e-05	0.000236	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTAFR—polycystic ovary syndrome	3.23e-05	0.000234	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	3.16e-05	0.000229	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ADRA1D—polycystic ovary syndrome	3.14e-05	0.000227	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FSHR—polycystic ovary syndrome	3.14e-05	0.000227	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—CYP1A1—polycystic ovary syndrome	3.07e-05	0.000223	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—POMC—polycystic ovary syndrome	3.07e-05	0.000222	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.05e-05	0.000221	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.05e-05	0.000221	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	3.03e-05	0.000219	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	3.02e-05	0.000219	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	3e-05	0.000217	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	3e-05	0.000217	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—INHBB—polycystic ovary syndrome	2.98e-05	0.000216	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RACGAP1—polycystic ovary syndrome	2.95e-05	0.000214	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	2.95e-05	0.000214	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	2.89e-05	0.00021	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	2.89e-05	0.00021	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—POMC—polycystic ovary syndrome	2.88e-05	0.000209	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—POMC—polycystic ovary syndrome	2.88e-05	0.000209	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.87e-05	0.000208	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—INS—polycystic ovary syndrome	2.87e-05	0.000208	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—INS—polycystic ovary syndrome	2.87e-05	0.000208	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	2.86e-05	0.000207	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	2.83e-05	0.000205	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FST—polycystic ovary syndrome	2.8e-05	0.000203	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.78e-05	0.000201	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PDE3B—polycystic ovary syndrome	2.78e-05	0.000201	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.77e-05	0.000201	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	2.77e-05	0.000201	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.77e-05	0.000201	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	2.77e-05	0.000201	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.76e-05	0.0002	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—LHB—polycystic ovary syndrome	2.73e-05	0.000198	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—GHRL—polycystic ovary syndrome	2.71e-05	0.000196	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NMNAT3—polycystic ovary syndrome	2.7e-05	0.000196	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	2.69e-05	0.000195	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	2.68e-05	0.000194	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.67e-05	0.000193	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.63e-05	0.000191	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.63e-05	0.000191	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	2.63e-05	0.00019	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.58e-05	0.000187	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	2.58e-05	0.000187	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.58e-05	0.000187	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SCT—polycystic ovary syndrome	2.56e-05	0.000185	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FSHR—polycystic ovary syndrome	2.53e-05	0.000183	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.52e-05	0.000183	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	2.52e-05	0.000183	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—POMC—polycystic ovary syndrome	2.48e-05	0.000179	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—LPCAT2—polycystic ovary syndrome	2.47e-05	0.000179	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SUOX—polycystic ovary syndrome	2.47e-05	0.000179	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—GHRL—polycystic ovary syndrome	2.46e-05	0.000178	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	2.45e-05	0.000178	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	2.44e-05	0.000177	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.44e-05	0.000177	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FGF18—polycystic ovary syndrome	2.4e-05	0.000174	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RACGAP1—polycystic ovary syndrome	2.38e-05	0.000172	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RBP4—polycystic ovary syndrome	2.38e-05	0.000172	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.37e-05	0.000171	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.34e-05	0.00017	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	2.33e-05	0.000169	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.31e-05	0.000168	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ISYNA1—polycystic ovary syndrome	2.3e-05	0.000166	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—POMC—polycystic ovary syndrome	2.29e-05	0.000166	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	2.29e-05	0.000166	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	2.29e-05	0.000166	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FST—polycystic ovary syndrome	2.26e-05	0.000163	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	2.25e-05	0.000163	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.24e-05	0.000162	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.23e-05	0.000161	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—YAP1—polycystic ovary syndrome	2.22e-05	0.000161	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LHB—polycystic ovary syndrome	2.2e-05	0.000159	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	2.2e-05	0.000159	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GAB1—polycystic ovary syndrome	2.19e-05	0.000159	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	2.16e-05	0.000157	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.15e-05	0.000156	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.12e-05	0.000154	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.12e-05	0.000154	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	2.1e-05	0.000152	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—INSR—polycystic ovary syndrome	2.09e-05	0.000152	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.08e-05	0.000151	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.08e-05	0.000151	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SCT—polycystic ovary syndrome	2.06e-05	0.000149	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.04e-05	0.000148	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	1.99e-05	0.000144	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.99e-05	0.000144	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.97e-05	0.000143	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.96e-05	0.000142	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TEAD2—polycystic ovary syndrome	1.95e-05	0.000142	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKR1C2—polycystic ovary syndrome	1.95e-05	0.000142	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PGR—polycystic ovary syndrome	1.94e-05	0.00014	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGF18—polycystic ovary syndrome	1.93e-05	0.00014	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RBP4—polycystic ovary syndrome	1.92e-05	0.000139	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	1.92e-05	0.000139	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	1.91e-05	0.000138	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.89e-05	0.000137	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	1.88e-05	0.000136	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	1.85e-05	0.000134	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	1.82e-05	0.000132	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.81e-05	0.000131	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.81e-05	0.000131	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GHRL—polycystic ovary syndrome	1.8e-05	0.00013	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PLAT—polycystic ovary syndrome	1.8e-05	0.00013	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—YAP1—polycystic ovary syndrome	1.79e-05	0.00013	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GAB1—polycystic ovary syndrome	1.77e-05	0.000128	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.74e-05	0.000126	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	1.73e-05	0.000126	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ATF1—polycystic ovary syndrome	1.72e-05	0.000124	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.71e-05	0.000124	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—INSR—polycystic ovary syndrome	1.69e-05	0.000122	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.68e-05	0.000121	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.67e-05	0.000121	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PNPLA2—polycystic ovary syndrome	1.64e-05	0.000119	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.6e-05	0.000116	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NGFR—polycystic ovary syndrome	1.59e-05	0.000115	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.58e-05	0.000114	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—POMC—polycystic ovary syndrome	1.58e-05	0.000114	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PRL—polycystic ovary syndrome	1.57e-05	0.000114	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PGR—polycystic ovary syndrome	1.56e-05	0.000113	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	1.55e-05	0.000112	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	1.54e-05	0.000112	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.52e-05	0.00011	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.49e-05	0.000108	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	1.48e-05	0.000107	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	1.47e-05	0.000107	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	1.46e-05	0.000106	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.46e-05	0.000105	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PLAT—polycystic ovary syndrome	1.45e-05	0.000105	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GHRL—polycystic ovary syndrome	1.45e-05	0.000105	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.4e-05	0.000101	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ATF1—polycystic ovary syndrome	1.39e-05	0.0001	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GNAS—polycystic ovary syndrome	1.38e-05	0.0001	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.38e-05	0.0001	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.35e-05	9.79e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.35e-05	9.75e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	1.34e-05	9.73e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	1.32e-05	9.56e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.32e-05	9.54e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	1.31e-05	9.51e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRG1—polycystic ovary syndrome	1.29e-05	9.37e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NGFR—polycystic ovary syndrome	1.28e-05	9.27e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	1.27e-05	9.21e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—POMC—polycystic ovary syndrome	1.27e-05	9.21e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PRL—polycystic ovary syndrome	1.27e-05	9.19e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	1.26e-05	9.12e-05	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-05	9.08e-05	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-05	9.08e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	1.24e-05	9.01e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.22e-05	8.85e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.2e-05	8.71e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	1.18e-05	8.55e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	1.17e-05	8.48e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	1.15e-05	8.32e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	1.13e-05	8.21e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	1.12e-05	8.13e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	1.12e-05	8.08e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.11e-05	8.02e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	1.09e-05	7.92e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	1.09e-05	7.87e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.08e-05	7.85e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.06e-05	7.7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	1.05e-05	7.6e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.04e-05	7.56e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	1.04e-05	7.56e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	1.04e-05	7.51e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.03e-05	7.46e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	1e-05	7.25e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	9.79e-06	7.09e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	9.69e-06	7.02e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	9.67e-06	7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	9.64e-06	6.98e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	9.34e-06	6.76e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	9.31e-06	6.74e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	9.26e-06	6.71e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	8.97e-06	6.5e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	8.96e-06	6.49e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	8.95e-06	6.48e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	8.94e-06	6.47e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	8.92e-06	6.46e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	8.86e-06	6.42e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	8.8e-06	6.37e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	8.74e-06	6.33e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.51e-06	6.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	8.37e-06	6.06e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TH—polycystic ovary syndrome	8.34e-06	6.04e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	8.24e-06	5.97e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	8.11e-06	5.88e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	7.8e-06	5.65e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	7.63e-06	5.53e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	7.51e-06	5.44e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	7.47e-06	5.41e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	7.23e-06	5.23e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	7.22e-06	5.23e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	7.13e-06	5.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	6.93e-06	5.02e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.86e-06	4.97e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	6.85e-06	4.96e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	6.81e-06	4.93e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	6.52e-06	4.72e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	6.49e-06	4.7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	6.15e-06	4.45e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.85e-06	4.24e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	5.82e-06	4.21e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	5.73e-06	4.15e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	5.54e-06	4.01e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	5.53e-06	4e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	5.25e-06	3.81e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	4.9e-06	3.55e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.72e-06	3.42e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	4.65e-06	3.37e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	4.58e-06	3.32e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—INS—polycystic ovary syndrome	4.56e-06	3.3e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	4.05e-06	2.93e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	3.97e-06	2.88e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	3.92e-06	2.84e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	3.9e-06	2.82e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	3.26e-06	2.36e-05	CbGpPWpGaD
